Pediatrix Medical Group, Inc. (NYSE:MD) Shares Purchased by Bailard Inc.

Bailard Inc. increased its holdings in shares of Pediatrix Medical Group, Inc. (NYSE:MD - Free Report) by 252.0% in the first quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 43,300 shares of the company's stock after purchasing an additional 31,000 shares during the quarter. Bailard Inc. owned 0.05% of Pediatrix Medical Group worth $627,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Proficio Capital Partners LLC acquired a new stake in Pediatrix Medical Group in the fourth quarter valued at approximately $404,000. Raymond James Financial Inc. acquired a new stake in Pediatrix Medical Group in the fourth quarter valued at approximately $3,066,000. Swiss National Bank grew its position in Pediatrix Medical Group by 2.8% in the fourth quarter. Swiss National Bank now owns 168,900 shares of the company's stock valued at $2,216,000 after acquiring an additional 4,600 shares in the last quarter. Natixis Advisors LLC acquired a new stake in Pediatrix Medical Group in the fourth quarter valued at approximately $232,000. Finally, Teacher Retirement System of Texas acquired a new stake in Pediatrix Medical Group in the fourth quarter valued at approximately $2,537,000. Institutional investors and hedge funds own 97.71% of the company's stock.

Pediatrix Medical Group Stock Down 2.1%

Shares of Pediatrix Medical Group stock traded down $0.27 on Friday, hitting $12.57. 543,188 shares of the company's stock traded hands, compared to its average volume of 720,427. The stock has a market cap of $1.08 billion, a P/E ratio of -12.45, a PEG ratio of 0.85 and a beta of 1.25. The company has a quick ratio of 1.81, a current ratio of 1.81 and a debt-to-equity ratio of 0.75. The firm's 50-day moving average is $13.83 and its 200 day moving average is $13.87. Pediatrix Medical Group, Inc. has a 52-week low of $7.40 and a 52-week high of $17.67.

Pediatrix Medical Group (NYSE:MD - Get Free Report) last released its earnings results on Tuesday, May 6th. The company reported $0.33 EPS for the quarter, beating the consensus estimate of $0.25 by $0.08. Pediatrix Medical Group had a positive return on equity of 17.43% and a negative net margin of 4.17%. The company had revenue of $458.36 million during the quarter, compared to analysts' expectations of $451.44 million. During the same period in the prior year, the business posted $0.20 EPS. The business's revenue was down 7.4% on a year-over-year basis. Equities analysts anticipate that Pediatrix Medical Group, Inc. will post 1.38 earnings per share for the current year.

Wall Street Analysts Forecast Growth

MD has been the subject of several recent research reports. UBS Group lowered their price objective on shares of Pediatrix Medical Group from $18.50 to $16.00 and set a "neutral" rating for the company in a research report on Monday, May 12th. Truist Financial reduced their target price on Pediatrix Medical Group from $18.00 to $16.00 and set a "hold" rating for the company in a research note on Friday, April 11th. Finally, Macquarie increased their target price on Pediatrix Medical Group from $19.00 to $20.00 and gave the company an "outperform" rating in a research note on Thursday, May 8th. Four research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Hold" and an average price target of $16.67.

Pediatrix Medical Group Profile

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.